Structure of cyclodextran (CI-8)

Cyclodextran, also known as cyclic isomaltooligosaccharide (CI), is a non-reducing sugar derived from dextran. It is characterized by its cyclized structure and composition of alpha-1,6 bonds.

Comparison with cyclodextrin edit

Although CI shares the common constituent of glucose, its linkage pattern is distinct from that of another cyclic oligosaccharide, cyclodextrin (CD), which consists of alpha-1,4 bonds. The structures of 11 types of CIs, with glucose units ranging from seven to seventeen, have been determined.[1] While CIs with high molecular weights, incorporating more than eighteen glucose units, also exist, research predominantly focuses on CIs with seven to twelve glucose units (CI-7 to CI-12) due to their higher prevalence and relative ease of purification.

History edit

Initial discovery edit

CI was first discovered in 1993. In a liquid culture using dextran as a carbon source, the researchers noticed that a strain of bacteria isolated from soil produced and accumulated a substance different from linear isomaltooligosaccharides.[2]

Natural occurrence edit

This substance, which was revealed to have a structure where 7 to 9 glucose molecules were connected in a circular fashion via alpha-1,6 bonds, was named cyclodextran. Given that dextran and isomaltooligosaccharides are naturally occurring, it was speculated that CI might also be a natural product. A trace amount of CI from CI-7 to CI-9 was confirmed when attempts were made to detect CI from brown sugar.[3]

Industrial production edit

Two methods are used to produce CI: one uses sucrose as a raw material to produce and cyclize dextran, and the other involves production from starch. Commercially, sucrose is the preferred raw material. CI is produced by applying the enzyme CITase to this dextran. A product known as CI-Dextran mix, which contains a mixture of CI and linear dextran, is currently on the market, and in Japan, it is provided by Nissin Sugar Co., Ltd.[4]

Functional properties edit

Inhibition of Glucosyltransferase (GTF) edit

CI specifically inhibits the activity of glucosyltransferase (GTF), a key enzyme in Streptococcus mutans, thereby suppressing the formation of glucan, a major component of dental plaque.[5]

Mechanism of action edit

The inhibition mechanism of GTF is presumed to be competitive inhibition where CI binds to the active site of GTF[6], but the detailed inhibition mechanism remains a subject for future research.

Solubility enhancement edit

The CI-Dextran mix has the effect of enhancing the solubility of some difficult-to-dissolve substances. However, it is not yet clear whether this effect is due to inclusion action like Cyclodextrin.

Chemical properties edit

One notable characteristic of CI is its lack of sweetness, indicating that it does not function as a sweetener. Due to its cyclic structure, CI has no terminal groups, and as a result, it does not exhibit reducing properties. CI is a sugar with strong stability against heat, acid, and alkali due to its cyclic structure. CI has high solubility in water and can dissolve in an equivalent or smaller amount of water.

Usage edit

Prevention of dental diseases edit

CI, a functional oligosaccharide, is suggested to potentially assist in the prevention of dental caries and periodontal disease. However, it's important to note that as of now, there is no definitive evidence that directly links CI to the prevention of dental caries and periodontal disease. This anticipated effect is based on its characteristic of inhibiting plaque formation, which is a known factor contributing to these dental diseases. Clinical trials are currently being planned to further explore these effects, and more data may become available in the near future.

Potential applications edit

CI's unique mechanism of action inhibits the glucosyltransferase (GTF), leading to a suppression of plaque formation without exhibiting bactericidal effects, meaning it does not harm beneficial bacteria. This characteristic of CI allows it to remain effective even when consumed alongside sugars. Its potential use extends to food, cosmetics, and possibly even over-the-counter drugs. A key advantage of CI, compared to other similar substances, is its ability to inhibit plaque formation without disturbing the balance of the oral microbiota, even in the presence of sugars.

References edit

  1. ^ Funane K, Terasawa K, Mizuno Y, Ono H, Gibu S, Tokashiki T, Kawabata Y, Kim YM, Kimura A, Kobayashi M (December 2008). "Isolation of Bacillus and Paenibacillus Bacterial Strains That Produce Large Molecules of Cyclic Isomaltooligosaccharides". Bioscience, Biotechnology, and Biochemistry. 72 (12): 3277–80. doi:10.1271/bbb.80384. PMID 19060390.
  2. ^ Oguma T, Horiuchi T, Kobayashi M (January 1993). "Novel Cyclic Dextrins, Cycloisomaltooligosaccharides, from Bacillus sp. T-3040 Culture". Bioscience, Biotechnology, and Biochemistry. 57 (7): 1225–27. doi:10.1271/bbb.57.1225. PMID 27281012.
  3. ^ Tokasiki T, Kinjyo K, Funane K, Itou H (2007). "Novel Cycloisomaltooligosaccharides Contained in the Kokuto Produced in Okinawa Prefecture". Journal of Applied Glycoscience. 54 (1): 27–30. doi:10.5458/JAG.54.27.
  4. ^ "CI-Dextran mix | Nissin Sugar Co., Ltd".
  5. ^ Kobayashi, Mikihiko; Funane, Kazumi; Oguma, Tetsuya (1995). "Inhibition of Dextran and Mutan Synthesis by Cycloisomaltooligosaccharides". Bioscience, Biotechnology, and Biochemistry. 59 (10): 1861–65. doi:10.1271/bbb.59.1861. PMID 8534976.
  6. ^ Kobayashi M, Oguma T (1995). "Cyclodextran and anti-dental-caries action". Japan Food Science. 34 (1): 26–31.